Approval · Notice of Compliance 33000 · 2024
RAPAMUNE: Notice of Compliance 33000
Issued April 4, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33000
- Date
- April 4, 2024
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to blister packaging mock-ups (package insert, carton label and blister label) for 1 mg tablet.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAPAMUNE | Not yet assigned | — |
Medicinal ingredients
- SIROLIMUS 1 MG per TAB